Clinical Trial Update: Toremifene in Treating Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 2 study of toremifene for ovarian cancer sponsored by George Washington University has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FARESTON (toremifene citrate)

Snippet

Sponsor: George Washington University | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN